Tuesday, 15 September 2015

2020 World Markets for Phenylketonuria (PKU)

Global Markets Direct's, 'Phenylketonuria (PKU) - Pipeline Review, H2 2015', provides an overview of the Phenylketonuria (PKU)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Phenylketonuria (PKU), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Phenylketonuria (PKU) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.


- The report provides a snapshot of the global therapeutic landscape of Phenylketonuria (PKU)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Phenylketonuria (PKU) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Phenylketonuria (PKU) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Phenylketonuria (PKU) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Table Of Content

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Phenylketonuria (PKU) Overview 6
Therapeutics Development 7
Pipeline Products for Phenylketonuria (PKU) - Overview 7
Pipeline Products for Phenylketonuria (PKU) - Comparative Analysis 8
Phenylketonuria (PKU) - Therapeutics under Development by Companies 9
Phenylketonuria (PKU) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Phenylketonuria (PKU) - Products under Development by Companies 12
Phenylketonuria (PKU) - Companies Involved in Therapeutics Development 13
BioMarin Pharmaceutical Inc. 13
Codexis, Inc. 14
Erytech Pharma SA 15
SOM Innovation Biotech SL 16
Phenylketonuria (PKU) - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Cell therapy for Phenylketonuria - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
pegvaliase - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Recombinant Enzyme to Replace Phenylalanine Hydroxylase for Phenyketonuria - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
sapropterin dihydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30

Request A Sample copy of This Report @ http://www.hexareports.com/sample/46626

SOM-7400 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Phenylketonuria (PKU) - Recent Pipeline Updates 33
Phenylketonuria (PKU) - Dormant Projects 36
Phenylketonuria (PKU) - Dormant Projects 36
Phenylketonuria (PKU) - Product Development Milestones 37
Featured News & Press Releases 37
May 22, 2015: Merck Serono Announces CHMP Positive Opinion to Extend Kuvan Use to Children with PKU Below 4 Years of Age 37
Mar 30, 2015: BioMarin Announces One Oral and 7 Poster Presentations at the 2015 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 37
Sep 24, 2014: FDA Receives Paragraph IV Notice Letter for KUVAN (sapropterin dihydrochloride) Tablets 40
Sep 03, 2014: Merck Announces Detailed 26-Week Results from Phase IIIb Study with Kuvan in Children with PKU Below 4 Years of Age 40
Apr 14, 2014: FDA Extends Market Exclusivity Six Months for BioMarin's Rare Disease Therapy KUVAN (sapropterin dihydrochloride) Powder for Oral Solution and Tablets 41
Jun 05, 2013: BioMarin Initiates Phase III Trial For PEG-PAL For Treatment Of Phenylketonuria 42
Feb 19, 2013: BioMarin Announces Kuvan Significantly Improves Inattentiveness In Phenylketonuria Patients 43
Sep 26, 2012: BioMarin Pharma To Initiate Phase III Program For PEG-PAL In Second Quarter Of 2013 43
Jun 30, 2011: Merck Serono Initiates Phase IIIb European Study SPARK In Children Younger Than Four Years, Suffering From Phenylketonuria 45
Mar 18, 2011: BioMarin Announces Preliminary Results From ADAPT Study 45
Appendix 48
Methodology 48
Coverage 48
Secondary Research 48
Primary Research 48
Expert Panel Validation 48
Contact Us 48

About Us:
Hexa Reports is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Information:

Ryan Shaw

Felton Office Plaza,
6265 Highway 9,
Felton, California, 95018,
United States
Phone Number

No comments:

Post a Comment